{"id":89863,"date":"2026-01-26T22:20:04","date_gmt":"2026-01-26T22:20:04","guid":{"rendered":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/glenmark-introduces-emergency-epinephrine-injection-drug-store-news\/"},"modified":"2026-01-26T22:20:04","modified_gmt":"2026-01-26T22:20:04","slug":"glenmark-introduces-emergency-epinephrine-injection-drug-store-news","status":"publish","type":"post","link":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/glenmark-introduces-emergency-epinephrine-injection-drug-store-news\/","title":{"rendered":"Glenmark introduces emergency epinephrine injection &#8211; Drug Store News"},"content":{"rendered":"<p>Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis. <\/p>\n<p>The medication is available in a pre-filled syringe and is administered via intramuscular injection, typically in the middle of the outer thigh. It is designed to provide fast and effective relief from severe allergic reactions, which can be caused by a range of allergens, including food, insect stings, and latex.<\/p>\n<p>The launch of the epinephrine injection by Glenmark is significant, as it provides patients with a more affordable alternative to branded products. The list price of Glenmark&#8217;s epinephrine injection is expected to be lower than that of Auvi-Q, making it a more accessible option for patients who require this life-saving medication.<\/p>\n<p>Glenmark&#8217;s epinephrine injection has been approved by the FDA in two doses: 0.3mg and 0.15mg. The 0.3mg dose is intended for patients who weigh 30kg or more, while the 0.15mg dose is intended for patients who weigh between 15kg and 30kg. The medication is available in a carton of two auto-injectors, each containing a single dose of epinephrine.<\/p>\n<p>The launch of Glenmark&#8217;s epinephrine injection is an important development for patients who are at risk of anaphylaxis. Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate medical attention. Symptoms of anaphylaxis can include difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, anaphylaxis can lead to serious health consequences, including death.<\/p>\n<p>Glenmark&#8217;s epinephrine injection provides patients with a reliable and effective treatment option for anaphylaxis. The medication has undergone rigorous testing and has been shown to be safe and effective in clinical trials. With its launch, Glenmark is helping to expand access to this critical medication, making it more widely available to patients who need it.<\/p>\n<p>Overall, the launch of Glenmark&#8217;s epinephrine injection is a significant development in the treatment of anaphylaxis. The medication provides patients with a fast and effective treatment option for severe allergic reactions, and its availability is expected to improve health outcomes for patients who are at risk of anaphylaxis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis. The medication is available in a pre-filled syringe and is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23,2],"tags":[],"class_list":["post-89863","post","type-post","status-publish","format-standard","hentry","category-glenmark","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89863,"position":0},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In &quot;Glenmark&quot;","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89851,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/25\/glenmark-pharmaceuticals-names-neha-jangale-as-new-head-of-learning-and-development\/","url_meta":{"origin":89863,"position":1},"title":"Glenmark Pharmaceuticals Names Neha Jangale as New Head of Learning and Development","author":"Team Small News","date":"January 25, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company's commitment to employee development and growth. Neha Jangale, with her extensive experience in the field of human resources, will\u2026","rel":"","context":"In &quot;Glenmark&quot;","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89871,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/28\/sun-pharma-receives-green-light-for-obesity-treatment-injection-similar-to-wegovy\/","url_meta":{"origin":89863,"position":2},"title":"Sun Pharma receives green light for obesity treatment injection similar to Wegovy.","author":"Team Small News","date":"January 28, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk's Wegovy. The new treatment, called \"SUN-144\", is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun\u2026","rel":"","context":"In &quot;Pharma&quot;","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89845,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/23\/a-recall-has-been-issued-for-a-batch-of-ms-medication-after-it-was-found-that-the-capsules-were-dissolving-at-a-slower-rate-than-expected\/","url_meta":{"origin":89863,"position":3},"title":"A recall has been issued for a batch of MS medication after it was found that the capsules were dissolving at a slower rate than expected.","author":"Team Small News","date":"January 23, 2026","format":false,"excerpt":"A batch of a multiple sclerosis (MS) medication has been recalled due to a manufacturing issue that affects the dissolution of the capsules. The medication, called Copaxone, is a glatiramer acetate injection used to treat relapsing forms of MS. The recall was initiated by the manufacturer, Teva Pharmaceuticals, after it\u2026","rel":"","context":"In &quot;Pharma&quot;","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89862,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/several-major-indian-pharmaceutical-companies-including-sun-pharma-cipla-zydus-and-graviti-have-issued-recalls-for-certain-medications-in-the-united-states-market\/","url_meta":{"origin":89863,"position":4},"title":"Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes. Sun Pharma is recalling over 24,000\u2026","rel":"","context":"In &quot;Cipla&quot;","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89863,"position":5},"title":"Dr Reddy&#8217;s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In &quot;Dr Reddy's&quot;","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89863"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89863\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}